NEW YORK, July 26, 2004, (PRIMEZONE) -- The following opinion is being issued by Investrend Research Syndicate:
Power3 Medical Products, Inc. (OTCBB:PWRM) has enrolled in the unique shareholder empowerment platform administered by Investrend Communications, Inc., a financial intelligence provider.
Criterion research coverage will be initiated by Investrend Research analyst Ryan Fuhrmann, CFA. Investrend Research is located on the web at http://www.investrendresearch.com, and the analyst's qualifications are at http://www.investrend.com/articles/secondlevel.asp?level=238.
Power3 Medical Products is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease.
The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
For more information, visit: http://www.power3medical.com
An InvestorPower(tm) page has been created regarding the company at http://www.investrend.com/company/list.asp?sPathParam=yes.
Ryan Fuhrmann, CFA, covered the Health Care industry as a member of the MBA Investment Fund, LLC, at the University of Texas School of Business. He will be taking a position with Standard and Poor's in their Corporate Valuation Consulting group in Dallas. He most recently covered the biotechnology industry for Houston-based Dyer, Robertson & Lamme. Prior to this, he was a portfolio manager in Chicago at Northern Trust Company where he managed individual discretionary and non-discretionary trust accounts. Mr. Fuhrmann is a Chartered Financial Analyst, member of the Association for Investment Management and Research and the Austin Financial Analyst Society.
Following the issuance of the report, the analyst will summarize the report on "AnalystBroadcast," available at Investrend Broadcast (http://www.investrendbroadcast.com), in partnership with VCall (http://www.vcall.com).
Investrend Research has been the leading independent equity research publishing and distribution program since 1996, with over 70 qualified professional analysts posting more than 700 reports to date. Anyone may enroll a company in the Investrend platforms. Enrollment fees for the "Criterion" research platform is $8,940, which has been paid by FOCUS Partners, LLC, the company's investor relations agency. Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage.
Anyone interested in receiving alerts regarding Power3 Medical Products research or webcasts should e-mail contact@investrend.com with "PRWM" in the subject line, or click on http://www.investrend.com/contact.asp.